5 recruiting, 1 active not recruiting, 1 completed, 1 unknown. 7 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Recruiting 4, Active not recruiting 1, Completed 1, Unknown 1 |
| Phase 2 | 6 | Recruiting 4, Active not recruiting 1, Unknown 1 |
Follow APG-115: new trials by email Literature Review of APG-115 trials Research Report on APG-115
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST APG-115, Selumetinib - Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1) | Phase 1 / Phase 2 | Recruiting | AeRang Kim | 45 | 2026-06-01 | 2026-07-27 |
| APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors APG-115, APG-2575 - Neuroblastoma, Solid Tumor | Phase 1 / Phase 2 | Recruiting | Ascentage Pharma Group Inc. | 100 | 2023-02-28 | 2026-08-21 |
| A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL APG-115, APG-2575 - T-Prolymphocytic Leukemia, Non-Hodgkins Lymphoma | Phase 2 | Recruiting | Ascentage Pharma Group Inc. | 78 | 2021-07-12 | 2025-11-04 |
| APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors APG-115, Toripalimab - Liposarcoma, Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Ascentage Pharma Group Inc. | 95 | 2021-05-26 | 2025-02-26 |
| A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS APG-115, 5-azacitidine - AML, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Ascentage Pharma Group Inc. | 69 | 2020-12-04 | 2024-02-01 |
| A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. APG-115, Azacitidine, Cytarabine - Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) | Phase 1 | Recruiting | Ascentage Pharma Group Inc. | 102 | 2020-07-06 | 2024-10-15 |
| APG-115 in Salivary Gland Cancer Trial APG-115, Carboplatin - Malignant Salivary Gland Cancer, Salivary Gland Cancer | Phase 1 / Phase 2 | Active not recruiting | University of Michigan Rogel Cancer Center | 41 | 2019-10-28 | 2026-07-13 |
| APG-115 in Patients With Advanced Solid Tumors or Lymphomas APG-115 - Patients With Advanced Solid Tumor or Lymphoma | Phase 1 | Completed | Ascentage Pharma Group Inc. | 50 | 2016-10-01 | 2022-07-12 |
Leukemia, Myeloid, Acute (2) · Myelodysplastic Syndromes (2) · Carcinoma, Adenoid Cystic (1) · Leukemia, Myelomonocytic, Chronic (1) · Leukemia, Prolymphocytic, T-Cell (1) · Liposarcoma (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Neuroblastoma (1) · Neurofibromatosis 1 (1) · Neurofibrosarcoma (1) · Salivary Gland Neoplasms (1)
Ascentage Pharma Group Inc. (6) · AeRang Kim (1) · University of Michigan Rogel Cancer Center (1)
United States (5) · China (3)
Yifan Zhai, MD, PhD (3) · AeRang Kim, MD, PhD (1) · Jianxiang Wang, M.D. (1) · Paul L Swiecicki, MD (1) · Ye Guo, MD, PhD (1) · Yizhuo Zhang (1)